Clinical trials: Normal Subjects, open to volunteers
Heart Failure With Reduced Ejection Fraction
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF).
- Trial name
- SALVADOR-HF (NCT06831825)
- Testing
- YAP101 (AAV9-Sav-shRNA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medley Therapeutics
Chronic Urticaria, Idiopathic
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
This Phase 2 study evaluates the efficacy and safety of MG-K10 in participants with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
- Trial name
- NCT07838727
- Testing
- MG-K10 Injection
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
High Grade Glioma, MGMT-Unmethylated Glioblastoma
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients.
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Trial name
- NCT06504381
- Testing
- DB107-RRV, DB107-FC, Radiation Therapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Hidradenitis Suppurativa (HS)
The Safety and Efficacy of Roflumilast Foam in HS
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- NCT07263230
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Advanced Non-small Cell Lung Cancer
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function
This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages.
- Trial name
- NCT06823245
- Testing
- HS-10241
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Breast Cancer, Lung Cancer
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- NCT06948539
- Testing
- TQB2101 for injection
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Systemic Sclerosis, Idiopathic Inflammatory Myopathies
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Conditions
- Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
- Trial name
- NCT06733935
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 240 people
- Sponsor
- Nkarta, Inc.
Androgenic Alopecia, Healthy Adult Male
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic…
- Trial name
- NCT07806474
- Testing
- formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast
- Where
- 6 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Activ'inside
Melanoma
A Study of IBI363 in Subjects With Advanced Melanoma
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
- Trial name
- NCT06081920
- Testing
- IBI363
- Where
- 12 sites in China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Netherton Syndrome
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
The goal of this clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (including up to the entire body [except the scalp]) works to treat the…
- Trial name
- NCT06953466
- Testing
- QRX003, 4% Lotion
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Quoin Pharmaceuticals
Pemphigus
A Clinical Study of B007 in the Treatment of Pemphigus.
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.
- Trial name
- NCT06454357
- Testing
- B007
- Where
- 12 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Oculocutaneous Albinism (OCA)
Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1)
Oculocutaneous albinism (OCA) is the most common type of albinism. People with OCA have little or no pigment (melanin) in their eyes, skin, and hair.
- Trial name
- NCT07313618
- Testing
- JWK010 gene therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- West China Hospital
Advanced Solid Tumor
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
- Trial name
- NCT05785741
- Testing
- DB-1310, Trastuzumab, Osimertinib
- Where
- 24 sites in United States, China
- Volunteers
- 1,000 people
- Sponsor
- DualityBio Inc.
Familial Pancreatic Cancer, BRCA1 Mutation
Registry of Subjects at Risk of Pancreatic Cancer
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
- Trial name
- IRFARPC (NCT04095195)
- Testing
- MRCP, Endoultrasonography
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
Glaucoma
Optic Nerve Head Strain in Non-glaucoma Subjects
Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure.
- Trial name
- NCT07425535
- Testing
- Latanoprost (0.005%)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Loiasis With Positive Blood Microfilaremia, Loiasis
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
- Trial name
- STOP-FiLAR-ALB (NCT06613997)
- Testing
- Albendazole 400mg
- Volunteers
- 100 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Pemphigus Vulgaris
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active…
- Trial name
- NCT04422912
- Testing
- DSG3-CAART, CABA-201
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cabaletta Bio
HR+/HER2-negative Breast Cancer
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria.
- Trial name
- NCT05683418
- Testing
- TOS-358, Fulvestrant, Palbociclib
- Where
- 18 sites in United States, Spain
- Volunteers
- 241 people
- Sponsor
- Totus Medicines
Healthy Adult Participants
A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)
The purpose of this study is to test the AdaptDx Pro agreement in Rod Intercept (RI) time with the AdaptDx tabletop (AdaptDx) in healthy subjects with normal vision.
- Trial name
- FlashBack (NCT07803588)
- Testing
- AdaptDx Tabletop vs AdaptDx Pro
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AdaptDx, Inc.